Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Kowa Pharmaceuticals America.

    Client Virtual Booth

    KOWA PHARMACEUTICALS AMERICA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Kowa Pharmaceuticals America
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    530 Industrial Park Boulevard Montgomery, AL 36117
    Telephone
    Telephone
    334.288.1288
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kowapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kowapharmaceuticalsamericainc/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan

    Details:

    The agreement granting Kowa to focus on the development and commercialization of NCX470 (bimatoprost), Nicox’s nitric oxide, which is used for the lowering of intraocular pressure in patients with glaucoma or ocular hypertension.


    Lead Product(s): Bimatoprost

    Therapeutic Area: Ophthalmology Product Name: NCX 470

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: Nicox SA

    Deal Size: $32.8 million Upfront Cash: $3.2 million

    Deal Type: Licensing Agreement February 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS®(celecoxib 56-mg and tramadol hydrochlorid...

    Details:

    The primary efficacy endpoint met and studied was summed pain intensity difference from 0 to 48 hours (SPID0-48). SEGLENTIS (celecoxib) had a significantly greater effect on SPID0-48 (least-squares mean: −139.1 than tramadol, celecoxib or placebo.


    Lead Product(s): Celecoxib,Tramadol Hydrochloride

    Therapeutic Area: Neurology Product Name: Seglentis

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 19, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Kowa To Discontinue K-877 (Pemafibrate) "Prominent" Cardiovascular Outcomes Study

    Details:

    K-877 (pemafibrate), a highly potent and selective peroxisome proliferator activator receptor-alpha modulator for treatment of hyperlipidemia in Japan under brand name PARMODIA, will discontinue by DSMB who concluded that primary endpoint was unlikely to be met.


    Lead Product(s): Pemafibrate

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: K-877

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 08, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Esteve and Kowa Pharmaceuticals America Enter into an Exclusive License and Commercialization Agreement for Rights to E-58425

    Details:

    Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.


    Lead Product(s): Celecoxib,Tramadol Hydrochloride

    Therapeutic Area: Neurology Product Name: E-58425

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: Esteve Huayi Pharmaceutical

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement May 03, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search